Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-trastuzumab Emtansine-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-trastuzumab Emtansine

Published:2020-04 Issue:2 Volume:20 Page:e220-e228
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Modi Natansh D.,Sorich Michael J.,Rowland Andrew,McKinnon Ross A.,Koczwara Bogda,Wiese Michael D.,Hopkins Ashley M.

Funder

Pfizer

Cancer Council South Australia’s Beat Cancer Project

Cancer Council’s Beat Cancer Project

South Australian Department of Health

Beat Cancer Mid-Career Research

National Breast Cancer Foundation

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications;Iqbal;Mol Biol Int,2014

2. The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer;Diéras;Target Oncol,2014

3. Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial;Yan;Oncotarget,2017

4. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial;Hurvitz;Lancet Oncol,2018

5. Trastuzumab emtansine for HER2-positive advanced breast cancer;Verma;N Engl J Med,2012

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Partial response to trastuzumab deruxtecan (DS8201) following progression in HER2-amplified breast cancer with pulmonary metastases managed with disitamab vedotin (RC48): a comprehensive case report and literature review;Frontiers in Oncology;2024-06-17

2. Utilization and safety of trastuzumab emtansine (T-DM1): a nationwide population-based study using the French National Health Data System;ESMO Real World Data and Digital Oncology;2024-06

3. mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation;Frontiers in Oncology;2024-01-25

4. Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages;JAMA Oncology;2023-12-01

5. RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study;BMC Cancer;2023-11-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3